drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CD19-directed CAR T cells)
drug_description
Autologous, gene‑modified CD19‑directed CAR T‑cell therapy (CARTEYVA). Patient T cells are engineered to express an anti‑CD19 chimeric antigen receptor with 4‑1BB costimulatory and CD3ζ signaling domains; upon binding CD19 on B‑cell lymphomas, the CAR T cells expand and mediate perforin/granzyme‑dependent cytotoxicity, leading to B‑cell depletion.
nci_thesaurus_concept_id
C155878
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express an anti-CD19 chimeric antigen receptor with 4-1BB costimulatory and CD3ζ signaling domains; upon binding CD19 on malignant B cells, the CAR T cells activate, expand, and kill targets via perforin/granzyme-mediated cytotoxicity, depleting CD19-positive B-cell lymphomas.
drug_name
Relmacabtagene autoleucel
nct_id_drug_ref
NCT05814848